The Institute for Clinical and Economic Review, known for its critiques of drug prices, is training its sights on health plan restrictions to medicines. “The national debate about drug pricing has focused great attention on methods to determine whether the price of a drug is ‘fair’ or ‘reasonable’,” ICER states in a summary of its work. “A question far less examined is how to determine whether insurance coverage is providing fair access to that drug.” Drug lobbyists and patient advocates...